EGFR and colorectal carcinoma: All currently approved immunotherapies for CRC consist of monoclonal antibodies (mAbs), and include the likes of the anti-vascular endothelial growth factor (VEGF) mAb bevacizumab (Genentech), and the anti-epidermal growth factor receptor (EGFR) mAbs cetaximab (ImClone LLC) and panitumumab (Amgen) [42–44].